Somatropin

4 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs

Human trial2
Humans1

Outcomes

Weight growth

upin humans1+50% weight growth

1 study

Somatropin increases weight growth in humans (+50% weight growth).
“Growth hormone treatment in a few patients increased height growth by 10% and weight growth by 50%.”
Human trialn = 15
Phenotype and course of Hutchinson-Gilford progeria syndrome
The New England journal of medicine7 Feb 2008

Height growth

upin humans1+10% height growth

1 study

Somatropin increases height growth in humans (+10% height growth).
“Growth hormone treatment in a few patients increased height growth by 10% and weight growth by 50%.”
Human trialn = 15
Phenotype and course of Hutchinson-Gilford progeria syndrome
The New England journal of medicine7 Feb 2008

Associations

Diabetes or glucose intolerance

upin humans1

1 study

Somatropin raises the risk of diabetes or glucose intolerance in humans (18 vs 7 (P =.006)).
“Diabetes or glucose intolerance occurred in 18 GH-treated men vs 7 not receiving GH (P =.006).”
Human trial26 weeksmales
Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial
JAMA13 Nov 2002